Damon Runyon Researchers

Meet Our Scientists
Megan Insco, MD, PhD

Dr. Insco studies advanced melanoma. Melanoma initiation and drug resistance rely heavily on factors that control gene expression. Proteins called Cyclin Dependent Kinases (CDKs) show promise as drug targets in multiple difficult-to-treat cancers and are enabling a method to “drug” the previously “undruggable” process of gene expression. She aims to determine whether any of the transcriptional CDKs could be an effective drug target in advanced melanoma. 

Project title: "Investigating transcriptional cyclin dependent kinases as novel melanoma drug targets"
Institution: Boston Children's Hospital
Named Award: William Raveis Charitable Fund Fellow
Award Program: Fellow
Sponsor(s) / Mentor(s): Len Zon, MD
Cancer Type: Skin
Research Area: Animal Models/Mouse Models